A biotech startup has reported encouraging clinical trial results for its HIV vaccine, designed for post-infection administration, raising hopes for a potential cure for HIV, the virus that causes AIDS. "We may be on the brink of a breakthrough," stated the company's advisory board chairman.
Meanwhile, Chinese biotech companies are navigating a complex landscape of potential US funding limitations and tariffs, following proposed import duties of 60 to 100 per cent on Chinese goods by the US. These companies are exploring strategies to mitigate the impact, including expanding high-value product sales within China and seeking alternative overseas markets outside the US.
China's pharmaceutical industry is experiencing a boom, with 113 innovative drugs approved since the commencement of its 14th five-year plan in 2021. This figure nearly triples the number of approvals from the previous five-year plan, underscoring China's growing prominence in global drug development. This surge in innovation has propelled the market scale to US$13.8 billion, solidifying China's position as a global leader in the pharmaceutical sector.
